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Abstract
Introduction:  Controversy  surrounds  the  use  of  salvage  therapies  to  treat  sudden  sensorineu-
ral hearing  loss  (SSNHL),  with  no  consensus  on  recommendations.  While  several  studies  have
demonstrated  the  effectiveness  of  intratympanic  administration  of  steroids  (ITS)  and  hyperbaric
oxygen (HBO)  treatment,  few  have  compared  the  efﬁcacy  of  ITS  and  HBO  therapy  in  patients
with refractory  SSNHL.
Objective:  We  evaluated  the  efﬁciency  of  ITS  and  HBO  therapy  in  patients  with  refractory
SSNHL.
Methods: Patients  who  did  not  adequately  beneﬁt  from  systemic  treatment  were  evaluated
retrospectively.  Refractory  patients  were  deﬁned  as  those  who  gained  less  than  20  dB  in  hearing
after initial  treatment.  All  refractory  patients  were  informed  about  salvage  therapy  options:
ITS or  HBO  therapy,  the  advantages  and  disadvantages  of  which  were  explained  brieﬂy.  ITS
involved 4  mg/mL  dexamethasone  administered  through  a  25  gauge  needle.  Patients  underwent
HBO therapy  in  a  hyperbaric  chamber  where  they  breathed  100%  oxygen  for  120  min  at  2.5
atmospheric  pressure.  The  hearing  levels  of  both  groups  were  evaluated  before  the  salvage
therapy  and  at  3  months  after  treatment.  Improvements  in  hearing  were  evaluated  according
to the  Furahashi  criteria.  We  also  compared  the  two  therapies  in  terms  of  speech  discrimination
scores (SDSs)  and  the  recovery  of  all  frequencies.
Results:  The  salvage  therapies  generated  similar  results.  Changes  in  pure  tone  averages  and
SDSs were  similar  for  ITS  and  HBO  therapy  (p  =  0.364  and  p  =  0.113).  Comparison  of  SDSs  and
hearing thresholds  at  all  frequencies  showed  similar  levels  of  improvement. Please cite this article as: Gülüstan F, Yazıcı ZM, Alakhras WM, Erdur O, Acipayam H, Kufeciler L, et al. Intratympanic steroid
injection and hyperbaric oxygen therapy for the treatment of refractory sudden hearing loss. Braz J Otorhinolaryngol. 2016.
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Conclusion:  ITS  and  HBO  therapy  produced  similar  improvements  in  SSNHL  patients,  but  the
sample size  was  too  small  to  draw  deﬁnitive  conclusions.  Further  randomized  controlled  studies
are needed  to  identify  the  best  therapy  for  patients  with  refractory  sudden  hearing  loss.
© 2016  Associac¸a˜o  Brasileira  de  Otorrinolaringologia  e  Cirurgia  Ce´rvico-Facial.  Published
by Elsevier  Editora  Ltda.  This  is  an  open  access  article  under  the  CC  BY  license  (http://
creativecommons.org/licenses/by/4.0/).
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Injec¸ão de  intratimpânica  de  corticoides  e oxigenoterapia  hiperbárica  para  o
tratamento  da  perda  auditiva  súbita  refratária
Resumo
Introduc¸ão: Há  muita  controvérsia  envolvendo  o  uso  de  terapias  de  resgate  para  tratar  a  perda
auditiva neurossensorial  súbita  (PANSS),  sem  consenso  sobre  as  recomendac¸ões.  Embora  vários
estudos tenham  demonstrado  a  eﬁcácia  do  uso  de  corticoides  intratimpânicos  (CIT)  e  o  trata-
mento com  oxigenoterapia  hiperbárica  (HBO),  poucos  têm  comparado  a  eﬁcácia  da  terapia  ITS
e HBO  em  pacientes  com  PANSS  refratária.
Objetivo:  Avaliamos  a  eﬁciência  da  terapia  com  CIT  e  HBO  em  pacientes  com  PANSS  refratária.
Método:  Pacientes  que  não  se  beneﬁciaram  adequadamente  do  tratamento  sistêmico  foram
avaliados retrospectivamente.  Pacientes  refratários  foram  deﬁnidos  como  aqueles  que  gan-
haram menos  de  20  dB  na  audic¸ão  após  o  tratamento  inicial.  Todos  os  pacientes  refratários
foram informados  sobre  as  opc¸ões  de  terapia  de  resgate:  terapia  com  CIT  ou  HBO,  cujas  vanta-
gens e  desvantagens  foram  explicadas  brevemente.  O  CIT  envolveu  4  mg/mL  de  dexametasona
administrada  através  de  uma  agulha  de  calibre  25.  Os  pacientes  foram  submetidos  à  terapia
HBO em  uma  câmara  hiperbárica  onde  respiraram  100%  de  oxigênio  por  120  min  a  2,5  pressão
atmosférica.  Os  níveis  de  audic¸ão  de  ambos  os  grupos  foram  avaliados  antes  da  terapia  de
resgate e  três  meses  após  o  tratamento.  As  melhorias  na  audic¸ão  foram  avaliadas  de  acordo
com os  critérios  de  Furahashi.  Também  comparamos  as  duas  terapias  em  termos  de  Escores  de
Discriminac¸ão de  Fala  (EDF)  e  a  recuperac¸ão  de  todas  as  frequências.
Resultados:  As  terapias  de  resgate  demonstraram  resultados  semelhantes.  As  alterac¸ões  nas
médias de  tons  puros  e  nas  EDF  foram  semelhantes  para  a  terapia  com  CIT  e  HBO  (p  =  0,364  e
p =  0,113).  A  comparac¸ão  dos  EDF  e  dos  limiares  de  audic¸ão  em  todas  as  frequências  mostrou
níveis de  melhora  semelhantes.
Conclusão:  CIT  e  HBO  produziram  melhorias  semelhantes  nos  pacientes  com  PANSS,  mas  o
tamanho da  amostra  era  muito  pequeno  para  tirarmos  conclusões  deﬁnitivas.  Estudos  random-
izados e  controlados  adicionais  são  necessários  para  identiﬁcar  a  melhor  terapia  para  pacientes
com perda  auditiva  repentina  refratária.
©  2016  Associac¸a˜o  Brasileira  de  Otorrinolaringologia  e  Cirurgia  Ce´rvico-Facial.  Publicado
por Elsevier  Editora  Ltda.  Este e´  um  artigo  Open  Access  sob  uma  licenc¸a  CC  BY  (http://
creativecommons.org/licenses/by/4.0/).
I
T
r
a
c
t
i
a
m
t
v
t
i
s
n
t
h
r
c
u
s
r
I
o
b
S
i
introduction
he  widely  accepted  deﬁnition  of  sudden  sensorineu-
al  hearing  loss  (SSNHL)  is  loss  of  30  dB  or  more  for
t  least  3  days  at  three  consecutive  frequencies.  This
onstitutes  an  otologic  emergency  that  requires  urgent
reatment.  The  most  common  suggested  etiologies  are  per-
lymphatic  ﬁstulas,  viral  infections,  vascular  insufﬁciency,
nd  autoimmune  pathologies.1 Systemic  steroids  are  the
ost  widely  accepted  and  effective  drugs  for  treatment  of
he  condition.2 Steroids  can  be  used  orally,  intravenously,  or
ia  the  local  intratympanic  route,  particularly  in  combina-
ion  with  other  drugs.  With  steroid  therapy,  recovery  rates
ncrease  from  32--65%  to  49--89%.3 However,  after  the  initial
ystemic  treatment,  approximately  30--50%  of  patients  do
ot  show  an  adequate  response.4 For  these  patients,  salvage
herapies  offer  a  treatment  alternative.
i
s
SIntratympanic  administration  of  steroids  (ITS)  achieves
igher  perilymphatic  levels  compared  to  the  systemic
oute.5 It  also  prevents  systemic  side  effects,  allows  a  higher
oncentration  of  steroids  in  the  perilymph,  and  is  partic-
larly  beneﬁcial  in  patients  who  are  contraindicated  for
ystemic  steroids.  Therefore,  it  is  becoming  one  of  the  most
ecommended  treatment  options  for  patients  with  SSNHL.6
TS  can  be  used  as  a  primary  treatment,  salvage  treatment,
r  in  combination  with  systemic  steroids.  Its  efﬁcacy  has
een  demonstrated.7,8
Hyperbaric  oxygen  (HBO)  therapy  has  been  used  to  treat
SNHL  since  the  late  1970s.  It  is  recommended  when  hypoxia
s  thought  to  be  the  initial  cause  of  SSNHL  because  it
ncreases  blood  oxygen  levels  in  the  blood,  thereby  also
ncreasing  levels  in  the  perilymph  via  diffusion.9 Recent
tudies  have  demonstrated  that  HBO  therapy  is  effective  for
SNHL  patients  as  a  salvage  treatment.10--12
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Table  1  Criteria  used  for  audiologic  improvement  deﬁned
by Furahashi.13
Complete  recovery  PTA  25  ≤  dB  or  identical  to  the
contralateral,  non-affected  ear
Marked improvement  PTA  improvement  >  30  dB
Slight improvement  PTA  improvement  between  10
and 30  dB
Non-recovery  PTA  improvement  <  10  dB
PTA, four frequency pure-tone average (500, 1000, 2000,
a
p
(
d
s
m
t
t
i
q
a
e
s
R
I
4
t
a
H
w
s
a
(
7
r
d
m
4
2
g
b
T
i
s
(
T
a
iARTICLE
Intratympanic  steroid  injection  and  hyperbaric  oxygen  thera
Controversy  still  surrounds  salvage  therapies  in  SSNHL
with  no  consensus  of  the  best  treatment  option.  Several
studies  have  demonstrated  the  effectiveness  of  ITS  and  HBO
treatment  but  few  studies  have  compared  the  efﬁcacy  of  ITS
steroids  and  HBO  therapy  for  refractory  SSNHL.  This  was  the
aim  of  the  current  study.
Methods
The  medical  records  of  patients  hospitalized  due  to  SSNHL
between  March  2013  and  August  2015  were  evaluated  ret-
rospectively.  SSNHL  was  deﬁned  as  a  minimum  of  30  dB
hearing  loss  at  three  contiguous  frequencies  that  persisted
for  at  least  3  days.  All  patients  initially  received  intravenous
methylprednisolone  (250  mg)  on  the  ﬁrst  day,  followed
by  oral  methylprednisolone  at  1  mg/kg,  which  was  slowly
tapered  over  2 weeks.  Refractory  SSNHL  cases  were  deﬁned
as  those  that  showed  either  no  response  or  an  improvement
in  PTA  of  less  than  20  dB  at  the  end  of  the  second  week  of
initial  treatment.
All  refractory  SSNHL  patients  were  brieﬂy  informed  about
the  disadvantages  and  advantages  of  the  procedures  and
all  provided  written  informed  consent.  The  study  proto-
col  was  approved  by  the  local  ethics  committee  (approval
number:  2015/07/10).  We  excluded  SSHL  cases  with  an  iden-
tiﬁed  etiologic  factor,  including  previous  otologic  disease  or
operation,  retro-cochlear  lesions  diagnosed  by  magnetic  res-
onance  imaging,  any  infectious  or  autoimmune  diseases,  and
subjects  who  presented  for  primary  therapy  ≥30  days  after
onset  of  hearing  loss.  Patients  who  had  bilateral  SSNHL  and
those  under  age  18  years  were  also  excluded.  All  patients
were  informed  about  salvage  therapy  and  all  agreed  to
undergo  a  second-line  treatment,  either  ITS  injection  or  HBO
therapy.  The  advantages,  disadvantages,  and  complications
of  the  treatments  were  explained  prior  to  the  patient
choosing  their  desired  modality.  ITS  was  administered  three
times  weekly  for  3  weeks,  a  total  of  nine  doses,  under
local  anesthesia  with  10%  lidocaine  solution  (Xylocaine
®
;
Astra-Zeneca,  Cheshire,  United  Kingdom)  administered  via
a  cotton  ball  placed  within  the  external  auditory  canal
for  10  min.  Then,  approximately  1  mL  4  mg/mL  dexametha-
sone  (Dekort;  Deva  Co,  Istanbul,  Turkey)  was  injected  into
the  posterior--inferior  quadrant  of  the  tympanic  membrane
using  a  25  gauge  needle.13 The  patient’s  head  was  then
tilted  about  40◦ toward  the  healthy  side  for  20--30  min;  the
patient  was  advised  to  avoid  moving,  speaking,  swallowing,
or  coughing  during  this  period.  HBO  therapy,  chosen  by  27
patients,  consisted  of  21  sessions  administered  once  a day
over  3  weeks.  Patients  breathed  100%  oxygen  for  120  min  at
2.5  atmospheric  pressure  in  a  hyperbaric  chamber.  To  bal-
ance  middle  ear  pressure,  the  patients  were  told  to  swallow
if  they  felt  any  ear  discomfort.
A  single  audiologist  used  an  Inter-acoustics  AC40  clini-
cal  audiometer  for  audiologic  assessment.  The  hearing  level
on  the  15th  day  of  systemic  treatment  was  used  as  the  ini-
tial  audiometric  value  with  the  ﬁnal  audiometric  value  was
measured  2  months  after  treatment.  Improvement  in  PTA
was  evaluated  according  to  the  criteria  used  by  Furahashi,14
which  classiﬁes  the  outcome  as  complete  recovery,  marked
recovery,  partial  recovery,  or  non-recovery  (Table  1).  The
improvement  at  frequencies  of  250,  500,  1000,  2000,  4000,
i
g
m
t4000 Hz).
nd  8000  Hz  and  speech  discrimination  (SD)  were  also  com-
ared  before  and  after  the  treatment.
The  Number  Cruncher  Statistical  System  (NCSS)  2007
Kaysville,  UT,  USA)  was  used  for  statistical  analysis.  Stu-
ent’s  t  test  was  used  for  descriptive  statistics  (mean,
tandard  deviation,  median,  frequency,  rate,  minimum,
aximum)  as  well  as  to  compare  quantitative  data  in  the
wo  group  comparisons  of  parameters  showing  normal  dis-
ributions.  The  Mann--Whitney  U  test  was  used  to  compare
nitial  and  ﬁnal  audiometric  PTAs  and  values  for  each  fre-
uency  and  for  the  two-group  comparisons  of  parameters  in
bnormal  distribution.  Pearson’s  Chi-square  test  and  Fisher’s
xact  test  were  used  to  compare  qualitative  data.  Statistical
igniﬁcance  was  indicated  by  p  <  0.05.
esults
n  total,  57  refractory  SSNHL  patients  with  a  mean  age  of
2.05  ±  14.95  years  (range  18--67  years)  were  enrolled  in
his  study.  In  all,  30  patients  (52.6%)  were  treated  with  ITS
nd  the  remaining  27  patients  (47.4%)  were  treated  with
BO  therapy;  49.1%  (n  =  28)  were  women  and  50.9%  (n  =  29)
ere  men.  Descriptive  characteristics  of  the  two  groups  are
hown  in  Table  2. There  were  no  signiﬁcant  differences  in
ge,  sex,  time  at  which  treatment  began,  or  affected  side
p  >  0.05).
Before  salvage  treatment,  the  average  PTAs  were
1.47  ±  25.32  and  60.59  ±  22.75  in  the  ITS  and  HBO  group,
espectively,  and  there  were  no  statistically  signiﬁcant
ifferences  between  these  values  (p  >  0.05).  After  treat-
ent,  the  averages  decreased  to  51.27  ±  30.76  for  ITS  and
7.78  ±  24.43  for  HBO  therapy.  The  hearing  gains  were
0.20  ±  19.77  and  12.81  ±  13.31  in  the  ITS  group  and  HBO
roup,  respectively.  There  were  no  signiﬁcant  differences
etween  the  post-treatment  values  and  gains  (p  =  0.217).
he  changes  in  SDSs  were  16.13  ±  22.76  and  8.59  ±  16.14
n  the  ITS  and  HBO  groups,  respectively,  and  there  were  no
tatistically  signiﬁcant  differences  between  the  two  groups
p  =  0.113).
Complete  recovery  was  observed  in  12  (21.1%)  patients.
wenty-ﬁve  (43.9%)  patients  were  resistant  to  salvage  ther-
py,  and  were  deﬁned  as  the  non-recovery  group.  Partial
mprovement  was  noticed  in  12  patients  (21.1%)  and  marked
mprovement  was  noticed  in  8  patients  (14%).  When  the
roups  were  evaluated  in  terms  of  full  improvement,
arked  improvement,  or  partial  improvement  according
o  the  criteria  of  Furahashi,  no  signiﬁcant  differences
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Table  2  Descriptive  characteristics  of  the  groups.
Salvage  therapy  p
HBO  ITS
Mean  ±  SD Mean  ±  SD
Age  (years)  45.74  ±  14.87  38.73  ±  14.46  0.077a
The  interval  from  onset  to  therapy
Days  11.33  ±  6.44  9.50  ±  4.70  0.466b
Median  8  8
Salvage  therapy p
HBO  ITS
n (%)  n  (%)
Gender
Female  16  (59.3)  12  (40.0) 0.146c
Male  11  (40.7)  18  (60.0)
Ear side
Right  11  (59.3) 12  (40.0) 0.146c
Left  16  (40.7)  18  (60.0)
Chronic  disease
No  22  (81.5)  28  (93.3) 0.238d
Yes  5  (18.5)  2  (6.7)
ITS, intratympanic steroid; HBO, hyperbaric oxygen; SD, stan-
dard deviation.
a Student t test.
b Mann--Whitney U test.
c Pearson’s Chi-square test.
d Fisher’s Exact test.
Table  3  Hearing  recoveries  of  the  groups.
Salvage  therapies  p
HBO  ITS
n (%)  n  (%)
Full  recovery 0.837
No  21  (77.8)  24  (80.0)
Yes  6  (22.2)  6  (20.0)
Recovery  degree 0.364
No  13  (48.1)  12  (40.0)
Slight  7  (25.9)  5  (16.7)
Marked  7  (25.9)  13  (43.3)
Recovery  degree 0.536
No  13  (48.1)  12  (40.0)
Slight  +  marked  14  (51.9)  18  (60.0)
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ITS, intratympanic steroid; HBO, hyperbaric oxygen.
ere  detected  between  the  two  salvage  treatment  groups
p  > 0.05)  (Table  3).
iscussionn  the  majority  of  SSNHL  patients,  the  speciﬁc  cause  of  the
ondition  is  unknown  and  these  cases  are  referred  to  as  idio-
athic.  As  the  exact  etiopathogenesis  is  not  well  understood,
he  treatment  of  SSNHL  remains  controversial.  Alone  or  in
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ombination  with  other  treatments,  systemic  steroids  are
he  most  commonly  accepted  treatment  for  SSNHL.2 Addi-
ional  therapies  are  needed  for  the  patients  who  do  not
dequately  improve  with  initial  systemic  steroid  treatment.
ost  authors  support  the  beneﬁcial  effects  of  salvage  thera-
ies  and  favor  them  over  a  second  course  of  systemic  steroid
reatment,  because  ITS  and  HBO  therapy  are  associated  with
ewer  adverse  effects.
The  advantages  of  ITS  are  its  decreased  systemic  side
ffects  compared  to  systemic  steroid  administration  and  its
bility  to  deliver  a  higher  concentration  of  steroids  to  the
erilymph.5 Salvage  ITS  therapy  has  been  shown  to  provide
n  additional  hearing  gain  in  about  38--53%  of  patients.6,15
he  American  Academy  of  Otolaryngology  recommends  ITS
or  patients  who  exhibit  incomplete  recovery.  In  addition,
eta-analyses  that  investigated  the  efﬁcacy  of  ITS  as  a
alvage  treatment  demonstrated  signiﬁcant  reduction  in
earing  thresholds.6--18
In  our  clinic,  salvage  therapy  is  routinely  recommended
or  refractory  SSNHL  patients,  almost  all  of  them  opt  to
ndergo  a  second  line  treatment.  Both  salvage  therapies
ere  explained  to  all  patients,  30  of  them  chose  ITS  ther-
py.  The  average  PTA  of  the  ITS  group  was  71.47  ±  25.32
efore  the  treatment  and  51.27  ±  30.76  after  treatment.
he  mean  gain  was  20.20  ±  19.77  and  the  change  in  SDSs
as  16.13  ±  22.76.
Some  authors  have  suggested  that  ischemia  is  an  impor-
ant  pathologic  factor  in  the  development  of  SSNHL,  and
BO  therapy  is  thought  to  be  useful  for  these  patients.10--12
agahara  et  al.19 demonstrated  that  perilymphatic  oxygen
ension  is  signiﬁcantly  decreased  in  SSNHL  patients  com-
ared  to  controls.  Animal  studies  have  demonstrated  that
xygen  can  easily  diffuse  across  the  membranes  of  the  inner
ar  from  the  blood,  and  that  the  partial  pressure  of  oxy-
en  in  the  perilymph  of  the  inner  ear  increases  during  HBO
herapy.9 This  increased  oxygen  concentration  in  the  inner
ar  ﬂuids  may  nourish  sensorial  elements  of  the  cochlea.20
Many  studies  have  found  HBO  therapy  to  be  effective.20--22
n  recent  years,  some  authors  have  also  found  HBO  ther-
py  successful  as  a  salvage  therapy.10--12,23--25 Lamm  et  al.26
eported  a  meta-analysis  of  HBO  therapy  as  a  salvage  ther-
py  and  reported  a  hearing  gain  (>10  dB)  in  86%  of  patients.
n  our  study,  27  patients  agreed  to  undergo  HBO  therapy.
he  average  PTA  of  the  HBO  group  was  60.59  ±  22.75  before
he  treatment  and  47.78  ±  24.43  afterwards.  The  mean  gain
as  12.81  ±  13.31  and  the  change  in  SDSs  was  8.59  ±  16.14.
Few  studies  have  evaluated  the  efﬁciency  of  ITS  and  HBO
herapy  for  refractory  SSNHL  patients.  Yang  et  al.27 recently
ompared  salvage  therapy  using  HBO  and  ITS  treatments  and
ound  that  neither  modality  was  superior.  Cvoronic  et  al.28
ompared  HBO  therapy  and  ITS  for  salvage  treatment  in  a
andomized  prospective  study  and  found  that  both  options
ere  successful.  In  our  study  of  refractory  SSNHL  patients,
e  compared  the  hearing  gain  and  SDS  results  of  these  two
alvage  therapies,  which  produced  similar  hearing  gains  and
DSs.  ITS  therapy  showed  better  healing  in  terms  of  both
earing  gains  and  SDSs  compared  to  HBO  therapy  but  there
ere  no  statistically  signiﬁcant  differences  between  the
roups.
There  were  several  limitations  to  this  study.  First,  it
acked  randomization  and  a  control  group,  given  its  ret-
ospective  design.  Only  ﬁve  patients  declined  the  salvage
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Intratympanic  steroid  injection  and  hyperbaric  oxygen  thera
treatment,  which  yielded  a  small  control  group,  insufﬁcient
to  allow  effective  comparisons.  However,  the  main  aim  of
this  study  was  to  compare  ITS  and  HBO  therapy  as  salvage
treatments.
ITS  and  HBO  therapy  have  different  mechanisms:  ITS
reduces  inﬂammation  in  the  inner  ear  by  diffusion  via  the
round  window  while  HBO  therapy  increases  oxygen  concen-
tration  in  the  inner  ear  by  diffusion  from  the  blood,  thereby
aiding  the  recovery  of  affected  sensorial  elements  of  the
cochlea.  In  our  study,  ITS  treatment  yielded  better  hear-
ing  gains  than  did  HBO  therapy,  but  further  larger  studies
with  randomized  controlled  groups  are  needed  to  identify
the  best  treatment  for  refractory  SSNHL  patients.
Conclusion
ITS  and  HBO  therapy  showed  similar  results  in  SSNHL
patients,  but  further  randomized  controlled  studies  are
needed  to  demonstrate  the  best  therapy  for  patients  with
refractory  sudden  hearing  loss.
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